Results 171 to 180 of about 123,443 (349)

Vaporized cannabis versus placebo for acute migraine: A randomized, double‐blind, placebo‐controlled crossover trial

Headache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective To assess the efficacy of cannabis for the treatment of acute migraine. Background Preclinical and retrospective studies suggest cannabinoids may be effective in migraine treatment. However, there have been no randomized clinical trials examining the efficacy of cannabinoids for acute migraine.
Nathaniel M. Schuster, Mark S. Wallace, Thomas D. Marcotte, Dawn C. Buse, Euyhyun Lee, Lin Liu, Michelle Sexton   +6 more
wiley   +1 more source

New Insights into Cannabis Consumption; Abuses and Possible Therapeutic Effects [PDF]

, 2015
Cannabis is one of the oldest psychotropic drugs known to humanity. The paper assesses the current knowledge on the cannabis, including the mechanisms of action and the therapeutic potential of cannabinoids.
Baconi, Daniela Luiza, Bălălău, Cristian, Vasile, Robert Daniel   +2 more
core   +3 more sources

Anandamide, an Endogenous Cannabinoid, Inhibits Shaker-related Voltage-gated K+ Channels

, 1996
J.S. POLING, Michael A. Rogawski, N. Salem, Stefano Vicini   +3 more
openalex   +1 more source

Additional file 1 of Geotemporospatial and causal inference epidemiological analysis of US survey and overview of cannabis, cannabidiol and cannabinoid genotoxicity in relation to congenital anomalies 2001–2015

, 2022
Albert Stuart Reece, Gary Kenneth Hulse
openalex   +1 more source

Pathogenesis and Therapeutics for Chronic Pruritus of Unknown Origin: A Systematic Review

International Journal of Dermatology, EarlyView.
ABSTRACT Chronic pruritus of unknown origin (CPUO) is a distressing condition characterized by persistent itch lasting over 6 weeks without an identifiable cause. The underlying mechanisms remain poorly understood, complicating diagnosis and treatment.
Yagiz Matthew Akiska, Isha Gandhi, Robert Adler, Deena Fayyad, Perya Bhagchandani, Shabnam Afzal, Waleed Adawi, Shivani Patel, Shawn G. Kwatra   +8 more
wiley   +1 more source

Mitigating the Risk of QTc Prolongation When Using Haloperidol for Acute Treatment of Cannabinoid Hyperemesis Syndrome in Adolescents and Young Adults [PDF]

Sandra Merino, Lissette Tordera, Allison Jun, Sun Yang   +3 more
openalex   +1 more source

Annual Research Review: Neural mechanisms of eating disorders in youth – from current theory and findings to future directions

Journal of Child Psychology and Psychiatry, EarlyView.
Eating disorders are prevalent and profoundly debilitating psychiatric conditions with multifactorial etiology that frequently manifest during adolescence. This developmental stage is characterized by significant neurostructural and neurofunctional change, which may create a context conducive to the emergence of eating pathology.
Kelsey Hagan, E. Caitlin Lloyd, Sasha Gorrell   +2 more
wiley   +1 more source

Therapeutic Potential of Cannabinoids in Glaucoma – Hit or Myth? - A Review

Quality in Sport
Introduction: Glaucoma is a leading cause of irreversible blindness, characterized by elevated intraocular pressure (IOP) that damages the optic nerve.
Julia Górny, Alicja Kapciak, Tomasz Forenc, Jonasz Jurek , Aleksandra Pelczarska, Jaromir Hunia, Marcin Komorowski, Rafał Kaczorowski, Michał Janiszewski   +8 more
doaj   +1 more source

Limited effect of environmental stress on cannabinoid profiles in high‐cannabidiol hemp (Cannabis sativa L.)

, 2021
Jacob A. Toth, Lawrence B. Smart, Christine D. Smart, George M. Stack, Craig H. Carlson, Glenn Philippe, Jocelyn K. C. Rose   +6 more
openalex   +1 more source

Full‐Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) Improves Symptoms of Rett Syndrome: An Open‐Label Study

Journal of Paediatrics and Child Health, EarlyView.
ABSTRACT Aim The aim of this Phase I/II open‐label study was to assess the safety and efficacy of NTI164, a novel full‐spectrum medicinal cannabis plant extract 0.08% Δ‐9‐tetrahydrocannabinol (THC), in Rett syndrome (RTT). Methods Eleven female participants (5–16 years) with a pathogenic variant in the MECP2 gene were recruited to this study, receiving
B. A. Keating, Y. Ogru, T. G. Duthy, L. Douglas, K. Lichkus, E. Isikgel, M. C. Fahey, C. Ellaway   +7 more
wiley   +1 more source